NICE, SIGN & ESMO MELANOMA GUIDELINES

NICE have updated their Melanoma: assessment and management guideline [NG14] – 27 July 2022

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

In July 2022, they made new and updated recommendations on genetic testing, staging, surgery for stages 0 to III melanoma, anticancer treatment for people with stage III and IV melanoma, and follow-up.

You can find out more and read the updated guideline here.

This guideline includes recommendations on:

  • Communication and support
  • Managing vitamin D levels and drug treatment for other conditions
  • Assessing and staging melanoma
  • Managing stages 0 to II melanoma
  • Managing stage III melanoma
  • Treating in-transit metastases in stages III and IV melanoma
  • Managing stage IV and unresectable stage III melanoma
  • Follow-up treatment
Download the PDF version

SIGN 146: Cutaneous Melanoma

A National Clinical Guideline- January 2017 (currently under consultation)

This guideline provides advice at all stages of the patient’s pathway of care, from primary prevention to early recognition, treatment and follow up. It does not address melanomas of non-cutaneous origin such as melanomas arising from mucosae, ocular melanomas and other rare non-cutaneous sites.

The guideline should be of interest and relevance to primary care providers, dermatologists, surgeons,
pathologists, medical and clinical oncologists, public health physicians, nurses, health promotion professionals,
epidemiologists, radiologists, nuclear medicine physicians, general practitioners and patient support groups.

You can find out more here.

SIGN guideline cover
Download the guideline here

ESMO Guidelines

The ESMO Clinical Practice Guidelines on melanoma currently focus on cutaneous melanoma and include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
The ESMO consensus conference manuscript on locoregional melanoma was compiled by a multidisciplinary panel of experts and compiles recommendations with supporting evidence on controversial topics in melanoma management. Recommendations for locoregional melanoma in this manuscript include indications for SLNB and RLND, adjuvant targeted versus immunotherapy, adjuvant therapy in specific situations and adjuvant therapy toxicity management.

View locoregional melanoma guideline

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
The ESMO consensus conference manuscript on metastatic melanoma was compiled by a multidisciplinary panel of experts and compiles recommendations with supporting evidence on controversial topics in melanoma management. Recommendations for metastatic melanoma in this manuscript include targeted versus immunotherapy, treatment sequencing and duration and management of brain metastases.

View metastatic melanoma guidelines